Lanitop

Metildigoxin, the active ingredient in Lanitop, is a cardiac glycoside presented as an oral tablet for oral use. It is employed in the management of heart failure and atrial fibrillation, primarily in adult patients requiring improved cardiac contractility.

GNH USA supplies Lanitop as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory support for cross‑border distribution. Ensuring product integrity and timely delivery to end‑users through a robust logistics network.

Metildigoxin acts on the cardiac conduction system and myocardial contractility, providing therapeutic benefit in specific cardiovascular conditions.

- Heart failure: improves cardiac output and reduces symptoms of fluid overload. - Atrial fibrillation: helps control ventricular rate and may assist in rhythm management. - Atrial flutter: contributes to rate control and symptom relief.

Metildigoxin may cause a range of adverse reactions, some of which are frequent and others that are uncommon but potentially serious.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Vomiting: occasional episodes after dosing. - Diarrhea: loose stools, usually transient. - Fatigue: feeling of tiredness or weakness. - Blurred vision: visual disturbances, often reversible. - Dizziness: light‑headed feeling, especially on standing.

Serious or Rare Side Effects: - Cardiac arrhythmias: potentially life‑threatening rhythm disturbances. - Severe bradycardia: markedly slowed heart rate. - Heart block: impaired electrical conduction. - Hyperkalemia: elevated blood potassium levels. - Allergic reactions: rash, itching, or anaphylaxis. - Persistent visual changes: color‑vision abnormalities.

When prescribing Metildigoxin, clinicians should consider several safety measures to minimize risk.

- Renal impairment: adjust dose and monitor serum creatinine. - Electrolyte disturbances: check potassium and magnesium levels regularly. - Concomitant AV‑blocking drugs: avoid or use with caution. - Hypothyroidism: monitor thyroid function as sensitivity may increase. - Drug‑interaction review: assess all concurrent medications. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Metildigoxin interacts with a variety of medicines; some require avoidance while others need close monitoring.

Major Interactions (Avoid): - Other cardiac glycosides: additive toxicity. - Potassium‑sparing diuretics (e.g., spironolactone): risk of hyperkalemia. - Strong CYP3A4 inhibitors (e.g., ketoconazole): increased plasma levels. - Certain antiarrhythmics (e.g., amiodarone): heightened arrhythmic risk.

Moderate Interactions (Monitor Closely): - Loop diuretics: may alter electrolyte balance. - ACE inhibitors or ARBs: monitor blood pressure and renal function. - Beta‑blockers: assess for excessive bradycardia. - NSAIDs: can affect renal clearance and potassium homeostasis.